Bolt Biotherapeutics (NASDAQ:BOLT) Receives “Market Perform” Rating from SVB Leerink

SVB Leerink reissued their market perform rating on shares of Bolt Biotherapeutics (NASDAQ:BOLTFree Report) in a research report released on Wednesday morning, Benzinga reports. SVB Leerink currently has a $1.00 price target on the stock, down from their previous price target of $3.00.

Several other research analysts have also recently commented on BOLT. Stifel Nicolaus reiterated a hold rating and issued a $1.50 target price (down from $6.00) on shares of Bolt Biotherapeutics in a report on Wednesday. HC Wainwright reissued a neutral rating on shares of Bolt Biotherapeutics in a report on Wednesday. Finally, Guggenheim reiterated a neutral rating on shares of Bolt Biotherapeutics in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, Bolt Biotherapeutics has a consensus rating of Hold and an average price target of $3.50.

Get Our Latest Analysis on Bolt Biotherapeutics

Bolt Biotherapeutics Stock Down 3.9 %

NASDAQ:BOLT opened at $0.79 on Wednesday. The company has a market capitalization of $30.23 million, a price-to-earnings ratio of -0.48 and a beta of 1.05. The stock has a 50-day simple moving average of $1.18 and a 200 day simple moving average of $1.10. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.17 and a current ratio of 5.68. Bolt Biotherapeutics has a one year low of $0.79 and a one year high of $2.03.

Bolt Biotherapeutics (NASDAQ:BOLTGet Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.47) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.47). Bolt Biotherapeutics had a negative return on equity of 51.74% and a negative net margin of 556.59%. The company had revenue of $2.09 million during the quarter, compared to analyst estimates of $1.97 million. Sell-side analysts predict that Bolt Biotherapeutics will post -1.4 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. Newtyn Management LLC lifted its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLTFree Report) by 2.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,020,000 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Newtyn Management LLC owned 2.69% of Bolt Biotherapeutics worth $1,061,000 as of its most recent SEC filing. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.

Further Reading

Analyst Recommendations for Bolt Biotherapeutics (NASDAQ:BOLT)

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.